1Department of Gastroenterology, Dayanand Medical College & Hospital, Ludhiana, India
2School of Biotechnology, Jawaharlal Nehru University, New Delhi, India
3Department of Internal Medicine, Dayanand Medical College & Hospital, Ludhiana, India
4Multidisciplinary Centre for Advanced Research and Studies (MCARS), Jamia Millia Islamia, New Delhi, India
5Department of Pathology, Dayanand Medical College & Hospital, Ludhiana, India
6Department of Pharmacology, Dayanand Medical College & Hospital, Ludhiana, India
© Copyright 2019. Korean Association for the Study of Intestinal Diseases. All rights reserved.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
FINANCIAL SUPPORT
The authors received no financial support for the research, authorship, and/or publication of this article.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTION
All authors have contributed to and agreed on the content of the manuscript, and the respective roles of each author are listed below:
Sood A and Mahajan R: conception and design; collection, analysis and interpretation of the data; drafting of the article; critical revision of the article for important intellectual content; final approval of the article. Juyal G: analysis and interpretation of the data; drafting of the article; critical revision of the article for important intellectual content; final approval of the article. Midha V: conception and design; analysis and interpretation of the data; drafting of the article; critical revision of the article for important intellectual content; final approval of the article. Grewal CS: collection, analysis and interpretation of the data, critical revision of the article for important intellectual content; final approval of the article. Mehta V: analysis and interpretation of the data, critical revision of the article for important intellectual content; final approval of the article. Singh A: collection, analysis and interpretation of the data; drafting of the article; critical revision of the article for important intellectual content; final approval of the article. Joshi MC: drafting of the article; critical revision of the article for important intellectual content; final approval of the article. Narang V, Kaur K, and Sidhu H: data analysis, critical revision of the article for important intellectual content; final approval of the article.
Characteristic | Case (n=41) |
---|---|
Age (yr) | 36.5±10.7 |
Male sex | 24 (58.5) |
Disease duration (yr) | 4.6±4.2 |
Mayo score | 8.8±2.6 |
Disease extent | |
E1 | 7 (17.1) |
E2 | 17 (41.5) |
E3 | 17 (41.5) |
Disease severity | |
Mild | 4 (9.8) |
Moderate | 37 (90.3) |
Concomitant medication | |
Mesalamine | 41 (100) |
Corticosteroids | 41 (100) |
Immunosuppressants (AZA) | 22 (53.7) |
Previous exposure to biological | 12 (29.3)a |
Timing of FMT | Week 0 | Week 2 | Week 6 | Week 10 | Week 14 | Week 18 | Week 22 |
---|---|---|---|---|---|---|---|
Mayo score | 8.9±2.5 | 7.7±1.9 | 6.4±2.3 | 5.7±1.9 | 4.8±1.9 | 4.4±1.9 | 3.1±1.7 |
Clinical remission | - | 0 | 3 (9.1) | 6 (18.2) | 7 (21.2) | 10 (30.3) | 19 (57.6) |
Clinical response | - | 11 (42.3) | 17 (51.5) | 22 (66.7) | 28 (84.8) | 29 (87.9) | 31 (93.9) |
Endoscopic remissiona | - | 4 (15.3) | 9 (27.3) | 12 (36.4) | 17 (51.5) | 21 (63.4) | 26 (78.8) |
Steroids successfully withdrawn | - | 1 (3.9) | 2 (6.1) | 15 (45.5) | 28 (84.8) | 29 (87.9) | 31 (93.9) |
Slurry retention time (hr) | 2.9±1.7 | 3.9±2.3 | 4.4±3.6 | 4.0±1.6 | 4.9±3.3 | 5.3±3.1 | 5.2±2.8 |
Study | Type of study | Country | No. of patients | Disease status | Donor | Route of administration | Frequency | Time of assessment (wk) | Clinical remission (%) | Clinical response (%) | Endoscopic remission (%) | Serious adverse events (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Moayyedi et al. [16] | RCT | Canada | 38 | Mild-moderate UC | Spouse (1 patient), volunteers (6 for other patients) | Rectal enema | Weekly-6 wk | 7 | 24.0 | 39.0 | 23.7 | 13.0 |
Rossen et al. [17] | RCT | The Netherlands | 23 | Mild-moderate UC | Healthy partners, relatives or volunteers | Nasoduodenal tube | Twice (0, 3 wk) | 12 | 30.4 | 47.8 | 8.7 | 8.7 (unrelated to FMT) |
Costello et al. [18] | RCT | Australia | 38 | Mild-moderate UC | Pooled donor stool (3–4 donors) | Colonoscopy followed by enemas | Baseline colonoscopy (wk 0), then 2 enemas at day 7 | 8 | 50.0 | - | 55.3 | 7.9 |
Paramsothy et al. [19] | RCT | Australia | 41 | Mild-moderate UC | Pooled donor stool (3–7 donors) | Colonoscopy followed by enemas | Baseline colonoscopy (wk 0), then 5 enemas weekly for 8 wk | 8 | 43.9 | 54.0 | 12.0 | 4.9 |
Present study | Real life cohort | India | 41 | Steroid dependent | Unrelated healthy volunteers | Colonoscopy | First 2 sessions fortnightly and then every 4 wk till 22 wk | 20 | 41.2 | 76.5 | 61.8 | None |
Characteristic | Case (n=41) |
---|---|
Age (yr) | 36.5±10.7 |
Male sex | 24 (58.5) |
Disease duration (yr) | 4.6±4.2 |
Mayo score | 8.8±2.6 |
Disease extent | |
E1 | 7 (17.1) |
E2 | 17 (41.5) |
E3 | 17 (41.5) |
Disease severity | |
Mild | 4 (9.8) |
Moderate | 37 (90.3) |
Concomitant medication | |
Mesalamine | 41 (100) |
Corticosteroids | 41 (100) |
Immunosuppressants (AZA) | 22 (53.7) |
Previous exposure to biological | 12 (29.3) |
Timing of FMT | Week 0 | Week 2 | Week 6 | Week 10 | Week 14 | Week 18 | Week 22 |
---|---|---|---|---|---|---|---|
Mayo score | 8.9±2.5 | 7.7±1.9 | 6.4±2.3 | 5.7±1.9 | 4.8±1.9 | 4.4±1.9 | 3.1±1.7 |
Clinical remission | - | 0 | 3 (9.1) | 6 (18.2) | 7 (21.2) | 10 (30.3) | 19 (57.6) |
Clinical response | - | 11 (42.3) | 17 (51.5) | 22 (66.7) | 28 (84.8) | 29 (87.9) | 31 (93.9) |
Endoscopic remission |
- | 4 (15.3) | 9 (27.3) | 12 (36.4) | 17 (51.5) | 21 (63.4) | 26 (78.8) |
Steroids successfully withdrawn | - | 1 (3.9) | 2 (6.1) | 15 (45.5) | 28 (84.8) | 29 (87.9) | 31 (93.9) |
Slurry retention time (hr) | 2.9±1.7 | 3.9±2.3 | 4.4±3.6 | 4.0±1.6 | 4.9±3.3 | 5.3±3.1 | 5.2±2.8 |
Study | Type of study | Country | No. of patients | Disease status | Donor | Route of administration | Frequency | Time of assessment (wk) | Clinical remission (%) | Clinical response (%) | Endoscopic remission (%) | Serious adverse events (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Moayyedi et al. [16] | RCT | Canada | 38 | Mild-moderate UC | Spouse (1 patient), volunteers (6 for other patients) | Rectal enema | Weekly-6 wk | 7 | 24.0 | 39.0 | 23.7 | 13.0 |
Rossen et al. [17] | RCT | The Netherlands | 23 | Mild-moderate UC | Healthy partners, relatives or volunteers | Nasoduodenal tube | Twice (0, 3 wk) | 12 | 30.4 | 47.8 | 8.7 | 8.7 (unrelated to FMT) |
Costello et al. [18] | RCT | Australia | 38 | Mild-moderate UC | Pooled donor stool (3–4 donors) | Colonoscopy followed by enemas | Baseline colonoscopy (wk 0), then 2 enemas at day 7 | 8 | 50.0 | - | 55.3 | 7.9 |
Paramsothy et al. [19] | RCT | Australia | 41 | Mild-moderate UC | Pooled donor stool (3–7 donors) | Colonoscopy followed by enemas | Baseline colonoscopy (wk 0), then 5 enemas weekly for 8 wk | 8 | 43.9 | 54.0 | 12.0 | 4.9 |
Present study | Real life cohort | India | 41 | Steroid dependent | Unrelated healthy volunteers | Colonoscopy | First 2 sessions fortnightly and then every 4 wk till 22 wk | 20 | 41.2 | 76.5 | 61.8 | None |
Values are presented as mean±SD or number (%). Infliximab (n=7) and adalimumab biosimilar (n=5). AZA, azathioprine.
Values are presented as mean±SD or number (%). Endoscopic remission was defined as Mayo endoscopic score 0 or 1. Of these patients, 0, 1, 2, 3, 3, 5, 7 patients had Mayo endoscopic score 0 at visits 1, 2, 3, 4, 5, 6, 7 respectively. FMT, fecal microbiota transplantation.
FMT, fecal microbiota transplantation; RCT, randomised controlled trial.